Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 29145547.
- Also identified by DOI 10.1001/jamaoncol.2017.3462 and PMC identifier 5833649.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study uses data from the National Cancer Database to examine the population-level efficacy of novel therapies for advanced-stage melanoma.
Medical subject headings
- Antibodies, Monoclonal
- Cell Cycle Checkpoints
- Immunotherapy
- Melanoma
- Molecular Targeted Therapy
- Protein Kinase Inhibitors
- Skin Neoplasms